[18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy

Herrera, Fernanda G.; Breuneval, Thomas; Prior, John O.; Bourhis, Jean; Ozsahin, Mahmut

doi:10.1186/s13014-016-0614-x

Table 2 Univariate analysis in 38 patients treated with cervical cancer treated with chemo-radiotherapy

From: [¹⁸F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy

Variable	n	3-y OS (%)	95 % CI	p	3-y DFS (%)	95 % CI	p	3-y LRC (%)	95 % CI	p
All patients	38	71	54–88	-	61	44–78	-	76	62–90	-
Age (years)
<50	22	41	27–49		63	61–65		72	69–75
				0.35			0.7			0.85
>50	16	78	74–82		53	50–56		77	60–94
Tumor size
≥4.5 cm	15	63	61–65		57	55–59		65	63–67
				0.5			0.56			0.19
<4.5 cm	23	82	80–84		68	65–71		84	68–100
Stage FIGO 2009
IB1, IIA1, IB2	8	71	68–74		57	55–59		71	67–75
IIA2, IIB	23	74	69–79	0.9	62	60–64	0.84	77	60–94	0.84
IIIA, IIIB, IVA	7	60	56–64		60	56–64		75	71–79
Histology
SCC	33	75	58–92		65	48–82	0.02*	79	65–93
				0.02*						0.15
Adenocarcinoma	5	50	45–55		26	21–31		50	45–55
LVSI
Positive	26	63	60–66		58	56–60		72	53–91
				0.87			0.62			0.55
Negative	12	65	62–68		66	63–69		83	81–85
Grade
1	3	66	61–71		66	61–71		66	61–71
2	18	56	54–58	0.81	53	52–55	0.92	85	71–99	0.33
3	17	84	82–86		69	67–71		69	67–71
Lymph nodes
Positive	22	55	52–58		60	57–63		76	58–94
				0.44			0.66			0.79
Negative	16	74	72–76		62	60–62		76	74–78
Hemoglobin (g/dl)
≥100	34	72	55–89		64	47–81		77	63–91
				0.6			0.1			0.46
<100	4	50	43–57		66	61–71		66	61–71
WBC (x10³/ml)
≥8.5	19	66	63–69		61	59–63		73	71–75
				0.95			0.83			0.44
<8.5	19	65	62–67		61	59–63		79	77–81
Median TGV (cm3)
≥255	19	59	57–61		52	50–54		69	66–72
				0.2			0.25			0.38
<255	19	79	77–81		70	68–72		82	65–99
TGV interquartile range (cm3)
≥562	29	37	27–43		33	30–36		55	52–58
				0.01*			0.002*			0.005*
<562	9	76	58–94		70	52–88		83	68–98
Tumor mean SUV (g/ml)
≥5	19	57	54–59		36	33–39		65	63–68
				0.03*			0.004*			0.04*
<5	19	86	72–100		88	70–100		88	78–98
Mean tumor SUVmax (g/ml)
≥15	14	61	55–65		53	45–58		62	58–69
				0.78			0.51			0.09
<15	24	78	73–83		66	60–72		85	75–90
Three-month post-treatment PET metabolic response
CMR	29	80	78–82		83			96	93–99
				0.0008*		68–98	<0.0001*			<0.0001*
PMR	9	30	27–33		0			22	19–25
MTV
≥69 cc	19	58	35–39		63	61–65		73	71–75
				0.65			0.47			0.35
<69 cc	19	73	55–61		63	61–65		81	62–100
Group
A + C	8	83	53–100		83	53–100		83	54–100
B + C	11	87	64–100	0.003*	90	73–100	0.0003*	90	73–100	0.03*
A + D	11	68	38–98		50	19–81		78	52–100
B + D	8	0	0		25	0–55		50	16–84

Table abbreviations:
OS Overall survival, DFS Disease-free survival, LRC Loco-regional control, CI Confidence interval, FIGO International Federation of Gynecology and Obstetrics staging system, TGV Total glycolytic activity within the tumor volume, SUV Standardized uptake value, SUVmax Maximum SUV, MTV Metabolic tumor volume, SCC Squamous cell carcinoma, LVSI Lympho-vascular space invasion, WBC White blood cells, CMR Complete metabolic response, PMR Partial metabolic response
Group categories: Group A + C: Patients with MTV below the median + patients with mean SUV below the median. Group A + D: Patients with MTV below the median + patients with mean SUV above the median. Group B + C: Patients with MTV above the median + patients with mean SUV below the median. Group B + D: Patients with MTV above the median + patients with mean SUV above the median
*p-values statistically significant

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com

Radiation Oncology

Contact us